Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.
Share
Why It Matters
A big investment bank raised its price guess for Biogen stock by $7. This means the company looks a bit stronger, but the bank still thinks it's a fair deal, not a great one.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.